Goldman Sachs Predicts Gold Prices To Surge To $3,700 By Late 2025

by News Editor

April 15, 2025

In a bold forecast, Goldman Sachs has increased its gold price prediction to $3,700 per ounce by the end of 2025. This adjustment comes amid unexpected demand from central banks and a strengthening perception of recession risks, drawing investors towards gold ETFs.

Key Points

Initial forecasts pegged the price at $3,300, but central banks’ monthly gold acquisitions, averaging 80 tons — much higher than the 17-ton average before 2022 — have warranted a forecast revision.
Gold prices have already seen a significant increase of over 23% in 2025, surpassing the $3,200 mark for the first time.
Should central banks continue acquiring at an accelerated pace, or if a recession prompts a capital influx into ETFs, gold could rise to $3,880 within this year.

What To Watch

Economists estimate a 45% chance of a U.S. recession within 12 months, potentially redirecting capital to gold ETFs. Should central banks ramp up purchases to 100 tons monthly, or recession-driven demand persist, gold might reach $3,880 by year-end. Alternatively, if economies show resilience and political uncertainty lessens, gold prices could stabilize around $3,550.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

The Future Forbes Realty Global Properties

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

by News Editor

September 3, 2026

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

Breaking news